Navigation Links
Affordable medicine plan goes global

An innovative plan to get new life-saving drugs into the hands of millions of people around the world who need medicines but can't afford the massive costs will be unveiled to key decision makers in London and Washington over the coming weeks.

"Pharmaceuticals have become an increasingly important part of health care, and you see that in the soaring amounts of money spent on them in developed countries like Canada and developing countries," says Aidan Hollis, an associate professor of economics at the University of Calgary and a key architect of the Health Impact Fund.

The steep cost of drugs has contributed to the deaths of millions of people in the developing world from diseases such as HIV-AIDS says Hollis. "And we're seeing this now play out with many new cancer-care drugs that are priced at a level even people in developed countries can't afford."

The Health Impact Fund, devised by Hollis and Thomas Pogge, Leitner Professor of philosophy and international affairs at Yale, will be presented to key government leaders, international aid agencies, NGOs, and pharmaceutical company representatives at Oxford, Cambridge, London, and Georgetown universities over the next three weeks.

"Currently, funding for drug innovation is based on people in rich countries paying taxes and drug insurance premiums to cover the exorbitant costs. Unfortunately, to sustain this system, poor people get excluded and the world is mainly comprised of poor people," says Hollis.

Hollis and Pogge propose a 'pay for performance' scheme in which drug companies would have the option to register their products with the HIF and sell the product for no more than the cost of production and distribution. In exchange, they would receive a stream of payments based on the assessed global health impact of each drug. The bigger the impact on worldwide health, the bigger the payout. And if there's no measurable health impact, there's no reward. Firms would only register their products if they expected to earn more from the HIF than from selling their products at high prices.

"The idea is that it's not the responsibility of the drug companies to ensure that everyone has access to these medicines. Charity by for-profit companies is not a sustainable solution," says Hollis. "By reorganizing the way we pay for pharmaceutical innovation, we can achieve wider access without extra costs. Patients win, and pharmaceutical companies also win."

Peter Singer, a bioethics professor at Princeton University and one of many collaborators involved in the project says: "The beauty of the scheme is that it gives economic support to the idea that all human lives are of equal value."

The estimated cost of this fund would be $6-billion annually, paid through a consortium of governments. Patients and insurance companies would then cover only the marginal cost of production and distribution. The key is getting buy-in from a number of governments worldwide.

Hollis admits that the timing is bad to be asking for cash during the current global economic crisis when the attention of the world's governments is focused elsewhere. But that doesn't mean the critical issue of drug accessibility is going away. "The U.S. has nearly 50 million people without health insurance who may not be getting the drugs they need and that's likely to increase with the weaker economy."

Pogge says Barack Obama's recent presidential election win suggests that the U.S. is more likely to be interested in such a proposal, which presents a unique opportunity for the country to regain some of the good will and moral stature it has lost in recent years.

"One very big difference this financial crisis makes is that we have to emphasize that the Health Impact Fund is advantageous for both rich and poor countries. It mustn't be perceived as merely a development-aid project. And I think that's relatively easy to do because in rich countries we also have problems with expensive drugs that insurance companies and national health systems won't pay for."

"Everyone can benefit when we treat research and development of pharmaceuticals as a global public good."


Contact: James Stevenson
University of Calgary

Related medicine news :

1. Publishes Safe Strategies for Drug Savings to Help All Americans Get Affordable Medication
2. DRE Medical Equipment Adds Affordable Refurbished Ultrasound Machines to Product Line
3. SEIU Member Will Be in Town Hall Audience, Ready to Ask John McCain Why He Wont Provide Affordable Healthcare for All
4. Catholic Health Initiatives Makes Major Gift to Support Affordable Housing in the Midwest
5. Social Network For Affordable Health Care Supporters Stimulates A New Level of Interactivity and Dialogue
6. Social Network for Affordable Health Care Supporters Stimulates a New Level of Interactivity and Dialogue
7. Quotebroker Expands Territory by Offering Affordable Health Insurance Quotes to Arizona Residents
8. Laboring Without Health Insurance? HSAs May Be an Affordable Option
9. Why Affordable HIV Testing Is More Important Than Ever: "HIV Epidemic 40% Higher Than Estimates"
10. AmeriPlan Offers Affordable Money-Saving Discount Healthcare Programs for the Uninsured and Underinsured
11. Making Healthcare More Affordable Is a National Priority
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... ... quoted Michael Hansen, Ph.D., a senior scientist at Consumer Reports as supporting a ... for a child’s exposure limits. , The original Nov 2015 CR story titled, ...
(Date:11/30/2015)... ... November 30, 2015 , ... While powdered supplements and drinks can reduce food ... inventor from Chesterfield, Va., has found an easy to keep track of the scoop. ... measure powdered contents in a canister or other container handy and readily accessible. As ...
(Date:11/30/2015)... ... November 30, 2015 , ... Medicalis, ... the Radiology Society of North America (RSNA) annual meeting, being held November 29 ... from 2014. Throughout 2015, the company has completed installations for Integrated Delivery ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... automated breast density assessment and enterprise analytics solutions, here at the 101st ... (South Hall booth #2377). Volpara’s quantitative breast imaging tools enable personalized measurements ...
(Date:11/30/2015)... ... November 30, 2015 , ... It’s inevitable that everyone will experience ... friend, or animal pass away, death lives among us. It is your perspective, however, ... a family of 11 children, author T Sky understands that she may see death ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... 2015  Precision Image Analysis Inc. (PIA), a ... announce a dramatic expansion of its capabilities as ... its ISO-9001:2008 certification for its Quality Management System, ... protocols and procedures. This expansion enables PIA to ... Core Lab services include design and optimization of ...
(Date:11/30/2015)... November 30, 2015 Mexico Healthcare and Life ... Sciences Report 2015 . --> Pharmaboardroom releases its new ... Latin America , a country of over 122 ... country of over 122 million people. --> It offers ... or life sciences insights into the second largest pharma and healthcare ...
(Date:11/30/2015)... 30, 2015 Elbit Imaging Ltd. ... announced today that it was informed by InSightec Ltd. ("InSightec"), ... (MFDS) has approved its Exablate Neuro system to treat ... --> Insightec,s Exablate Neuro platform is ... combines two technologies: Focused Ultrasound, which is used to ...
Breaking Medicine Technology: